Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17547
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrastianos, Priscilla K-
dc.contributor.authorIppen, Franziska Maria-
dc.contributor.authorHafeez, Umbreen-
dc.contributor.authorGan, Hui K-
dc.date2018-04-27-
dc.date.accessioned2018-05-02T01:04:23Z-
dc.date.available2018-05-02T01:04:23Z-
dc.date.issued2018-
dc.identifier.citationThe oncologist 2018; 23(9): 1063-1075-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17547-
dc.description.abstractPrimary and metastatic tumors of the central nervous system present a difficult clinical challenge, and they are a common cause of disease progression and death. For most patients, treatment consists primarily of surgery and/or radiotherapy. In recent years, systemic therapies have become available or are under investigation for patients whose tumors are driven by specific genetic alterations, and some of these targeted treatments have been associated with dramatic improvements in extracranial and intracranial disease control and survival. However, the success of other systemic therapies has been hindered by inadequate penetration of the drug into the brain parenchyma. Advances in molecular characterization of oncogenic drivers have led to the identification of new gene fusions driving oncogenesis in some of the most common sources of intracranial tumors. Systemic therapies targeting many of these alterations have been approved recently or are in clinical development, and the ability to penetrate the blood-brain barrier is now widely recognized as an important property of such drugs. We review this rapidly advancing field with a focus on recently uncovered gene fusions and brain-penetrant systemic therapies targeting them. Driver gene fusions involving receptor tyrosine kinases have been identified across a wide range of tumor types, including primary central nervous system (CNS) tumors and extracranial solid tumors that are associated with high rates of metastasis to the CNS (e.g., lung, breast, melanoma). This review discusses the systemic therapies that target emerging gene fusions, with a focus on brain-penetrant agents that will target the intracranial disease and, where present, also extracranial disease.-
dc.language.isoeng-
dc.subjectBrain metastasis-
dc.subjectEntrectinib-
dc.subjectGene rearrangement-
dc.subjectNon‐small cell lung cancer-
dc.subjectPrimary brain tumor-
dc.titleEmerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.-
dc.typeJournal Article-
dc.identifier.journaltitleThe oncologist-
dc.identifier.affiliationDepartment of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA-
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationAustin Health Clinical School of Nursing, La Trobe University, Heidelberg, Victoria, Australia -
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1634/theoncologist.2017-0614-
dc.identifier.pubmedid29703764-
dc.type.austinJournal Article-
dc.type.austinReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Feb 5, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.